• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors


Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

"...the answer is yes, we do need to be more aggressive in our drug therapy [against type 2 diabetes]. But I think the first thing is to recognize risk early, [for example] to deal with the problem of obesity as a society.

"It is crazy that it is so easy to end up with a BMI of 35 in our society now. We need to have social policy that helps us prevent that."

During a Patient Care interview, Dr John Buse was emphatic that waging a focused fight against risk factors for T2D is a far more rationale solution than placing one-third of the US population on 3 drugs as first-line therapy against the disease.

John B. Buse, MD, PhD is Distinguished Professor, Chief, Division of Endocrinology, Director, Diabetes Center, Executive Associate Dean for Clinical Research at the University of North Carolina School of Medicine at Chapel Hill.

Please see our accompanying interview with Dr Buse on newly reported findings from the GRADE study, including data that seem to favor insulin and GLP-1 RA therapy over a sulfonlyurea or DPP-4 inhibitor; Dr Buse also discusses T2D treatment selection based on comorbidities.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.